RecruitingPhase 3NCT06860971
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
A Randomized, Double-Blind, Multicenter Phase III Clinical Trial Evaluating AL2846 Capsule Versus Placebo in Patients With Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma Who Failed Prior VEGFR-Targeted Therapy
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Enrollment
144 participants
Start Date
Apr 18, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to demonstrate that, in subjects with locally advanced or metastatic iodine - refractory differentiated thyroid cancer who have failed previous VEGFR - targeted therapy, AL2846 can significantly prolong progression - free survival (PFS) compared with placebo.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria24
- Participants voluntarily join the study, sign the informed consent form, and demonstrate good compliance.
- Histologically or cytologically confirmed locally advanced or metastatic differentiated thyroid carcinoma (DTC).
- Age: 18 years ≤ age \<75 years (calculated based on the date of signing the informed consent form).
- Eastern Cooperative Oncology Group (ECOG) performance status score: 0-1.
- Anticipated survival \>12 weeks.
- At least one measurable lesion confirmed by RECIST 1.1 criteria.
- Disease progression (per RECIST 1.1) after receiving no more than 2 lines (no more than 3 types) lines of Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) therapy
- Confirmed iodine-refractory status, defined by \*\*one or more\*\* of the following:
- Lesions show no iodine uptake on post-Iodine-131 therapy whole-body scan and are unlikely to benefit from further Iodine-131 therapy.
- Previously iodine-avid lesions progressively lose iodine uptake after Iodine-131 therapy.
- Mixed iodine-avid and non-iodine-avid lesions in the same patient with no biochemical response.
- Iodine-avid lesions with disease progression (radiologically confirmed) within 12 months.
- Cumulative Iodine-131 dose ≥600 mCi (22 GBq) with no disease response (radiologically confirmed).
- Thyroid stimulating hormone (TSH) ≤0.5 mIU/L under TSH-suppressive therapy.
- Laboratory parameters meeting the following criteria:
- Hemoglobin (HGB) ≥90 g/L.
- Absolute neutrophil count (NEUT) ≥1.5×10⁹/L.
- Platelet count (PLT) ≥90×10⁹/L.
- Total bilirubin (TBIL) ≤1.5×ULN.
- Alanine aminotransferase (ALT) and Aspartate transferase (AST) ≤2.5×ULN.
- Creatinine clearance (CCR) ≥50 mL/min.
- Prothrombin time (PT), Activated partial thromboplastin time (APTT), and International Normalized Ratio (INR) ≤1.5×ULN (without anticoagulation therapy).
- Serum albumin (ALB) ≥30 g/L (no albumin infusion within 7 days prior to screening).
- For participants of childbearing potential: Agreement to use effective contraception during the study and for 6 months after study completion. Females must have a negative serum/urine pregnancy test within 7 days before enrollment; males must agree to effective contraception during and for 6 months post-study.
Exclusion Criteria7
- Patients with undifferentiated thyroid carcinoma or medullary thyroid carcinoma;
- Patients who have had or currently have other malignancies. The following two situations are eligible for enrollment: other malignancies treated with a single surgery and achieving a disease - free survival (DFS) of 5 consecutive years; cured cervical carcinoma in situ, non - melanoma skin cancer, and superficial bladder tumors \[Ta (non - invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)\].
- Those with multiple factors affecting oral medications (such as difficulty in swallowing, chronic diarrhea, and intestinal obstruction, etc.);
- Adverse reactions from previous treatments have not recovered to a Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. grade score ≤ 1, except for grade 2 alopecia, grade 2 peripheral neuropathy, grade 2 anemia, non - clinically significant and asymptomatic grade 2 laboratory abnormalities, and hypothyroidism stabilized by hormone replacement therapy, and other toxicities judged by the investigator to have no safety risks.
- Known allergy to the excipient components of the study drug.
- Subjects who have participated in and used other anti - tumor clinical trial drugs within 4 weeks before randomization.
- As judged by the investigator, there are situations that seriously endanger the safety of the subject or affect the subject's completion of the study.
Interventions
DRUGAL2846 Capsules
AL2846 Capsule is a multi - target tyrosine kinase inhibitor, which has significant inhibitory effects on c-Mesenchymal-epithelial transition factor (c - MET), stem cell factor receptor (c - KIT), VEGFR1 and Ret Proto-Oncogene (RET).
DRUGAL2846 Placebo
AL2846 Placebo without drug substance.
Locations(35)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06860971
Related Trials
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
NCT070925141 location
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations
Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.
NCT065078781 location
Studies on Tumors of the Thyroid
NCT000011601 location
Postoperative Hypocalcemia After Thyroidectomy
NCT074280571 location